Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

DEXTROMETHORPHAN FOR TREATMENT OF COMPLEX PARTIAL SEIZURES NEUROLOGY Fisher, R. S., CYSYK, B. J., Lesser, R. P., Pontecorvo, M. J., FERKANY, J. T., Schwerdt, P. R., Hart, J., GORDON, B. 1990; 40 (3): 547-549

Abstract

We performed a double-blind, crossover, add-on study of the antitussive agent dextromethorphan (DM 120 mg/d) as therapy for seizures on 9 patients suffering from severe complex partial seizures. DM had no significant influence on key laboratory values, nor on anticonvulsant drug levels. Side effects were negligible. Complex partial seizure frequency increased 25% during the DM arm of the study, although this increase was not clinically significant.

View details for Web of Science ID A1990CU48500036

View details for PubMedID 2314601